Oncotect Secures $125,000 Funding for Innovative Dog Cancer Screening Technology

Oncotect, a groundbreaking biotech startup based in Raleigh, has successfully raised $125,000 in funding to advance its revolutionary approach to canine cancer detection. Dedicated to ensuring the health and wellbeing of our beloved pets, Oncotect is pioneering an early screening method that utilizes urine samples to identify cancer risks in dogs, a revolutionary shift in veterinary diagnostics. The company has developed a patent-pending in-vitro test that harnesses proprietary technology along with the highly effective olfactory receptors of the C. elegans nematode, enabling it to detect cancerous volatile metabolites with remarkable precision. As the only urine-based screening test that is non-invasive, convenient, affordable, and accessible for multi-cancer detection in dogs, Oncotect stands at the forefront of veterinary medicine innovation. The newly acquired funding will be allocated towards enhancing research and development efforts, scaling production capabilities, and accelerating market entry, ultimately aiming to make early cancer detection an achievable reality for dog owners everywhere. With this funding, Oncotect is well-positioned to contribute significantly to the field of veterinary oncology, offering pet owners peace of mind as they take proactive steps in policing their dogs' health. As the numbers of pets impacted by cancer continue to rise, Oncotect’s commitment to affordable and accessible screening not only aims to extend the lives of dogs but also enhances the overall quality of life for both pets and their families.